Persistence Market Research is released upcoming report on title "Cancer Molecular Biomarkers Market: Global Industry Analysis and Forecast to 2020".

New York, NY -- (SBWire) -- 01/07/2015 --Cancer molecular biomarker refers to a natural occurring molecule or gene in the living organism that is an indicator for the presence of cancer in the body. Biomarker is a measurable indicator of biological process, condition or a disease and can be found in blood, tissues or other body fluids. Cancer molecular biomarkers help to diagnose cancer, and check the patient's response for treatment and certain cancer therapies. On the basis of diagnostics, cancer molecular biomarkers can be segmented into immunoassays, immunohistochemical (IHC) tests, genetic and genomic markers, proteomics, flow cytometry, stem cell markers, monoclonal antibodies, pharmacogenomics, DNA microarrays and IVD multivariate index assays (IVDMIA). On the basis of discovery, cancer molecular biomarkers can be segmented into genetic methods, protein methods and imaging. Genetic methods include DNA arrays, southern blot, polymerase chain reaction (PCR), fluorescent in situ hybridization (FISH) and reverse transcriptase polymerase chain reaction (RT-PCR). Protein methods include immunohistochemistry (IHC) and mass spectrometry (MS). Imaging methods include positron emission tomography (PET), computed tomography (CT), magnetic resonance spectroscopy (MRS), x-ray, ultrasound, magnetic resonance imaging (MRI) and biophotonics.

Buy Full Report:
http://www.persistencemarketresearch.com/market-research/cancer-molecular-biomarkers-market.asp

North America, followed by Europe, has the largest market for cancer molecular biomarkers due to growing IT industry, technological advancement for discovery of biomarker, rise in incidence of cancer cases, growing spending from government and private healthcare organizations in this field and developed healthcare infrastructure in this region. Asia is expected to experience high growth rate in the cancer molecular biomarkers market in next few years due to increasing research and development activities, rise in government involvement, growing awareness about cancer molecular biomarkers and developing healthcare infrastructure in the region.

Some of the factors such as technological advancement, increasing research and development activities, increasing funding from various government and non-government organizations, rise in healthcare expenditure, non-invasive technology, increasing prevalence of cancer cases and streamline drug delivery process are expected to drive the market for cancer molecular biomarkers. In addition, growing survival rates and increased accuracy of the diagnosis with the help of biomarker are expected to drive the market for cancer molecular biomarkers. However, issues related to the reimbursement, high cost of diagnosis, requirement of immediate processing, lack of awareness and various validation issues are some of the major factors restraining the growth for global cancer molecular biomarkers market.

Growing demographics and economies in the developing countries such as India and China is expected to lead the growth in cancer molecular biomarkers market in Asia. In addition, despite of high cost involved in R&D, pharmaceutical companies are showing increased interest in this field and innovations along with technological advancement such as emergence of genetic based in vitro diagnostics, enhanced therapeutic effectiveness and decrease in the severity of the adverse effects are expected to offer new opportunities for global cancer molecular biomarkers market. Increasing number of mergers and acquisitions, rise in number of collaborations and new product launches are some of the latest trends that have been observed in global cancer molecular biomarkers market. Some of the major companies operating in the global cancer molecular biomarkers market are Correlogic Systems, Inc., Agendia Bv, Biomerieux S.A, Aureon Laboratories, Inc., Astellas Pharma US Inc. and Becton. In addition, some other companies operating in the global cancer molecular biomarkers market are Diadexus, Inc., Abbott Laboratories, Affymetrix, Inc., Clarient, Inc, Biomoda, Inc., Beckman Coulter, Inc. and Dickinson and Company.

Request Full Toc:
http://www.persistencemarketresearch.com/toc/3841

Key points covered in the report:

1) Report segments the market on the basis of types, application, products, technology, etc (as applicable)

2) The report covers geographic segmentation

North America
Europe
Asia
RoW

3) The report provides the market size and forecast for the different segments and geographies for the period of 2010 to 2020

4) The report provides company profiles of some of the leading companies operating in the market
The report also provides porters five forces analysis of the market.

Browse related reports at:

1) Gelatin and Bone Glues Market: European Industry Analysis and Forecast to 2020

http://www.persistencemarketresearch.com/market-research/gelatin-bone-glues-market.asp

2) Clinical Decision Support Systems Market - Global Industry Analysis and Forecast to 2020

http://www.persistencemarketresearch.com/market-research/clinical-decision-support-systems-market.asp

3) Hospital-Acquired Infection Control Market: Global Industry Analysis and Forecast to 2020

http://www.persistencemarketresearch.com/market-research/hospital-acquired-infection-control-market.asp

4) Hospital Beds Market Global Industry Analysis and Forecast to 2020

http://www.persistencemarketresearch.com/market-research/hospital-beds-market.asp

About Persistence Market Research
Persistence Market Research (PMR) is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. PMR boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients' business needs.